Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

6.910 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32
Open 6.910
Bid (Size) 3.020 (100)
Ask (Size) 8.350 (1,000)
Prev. Close 6.910
Today's Range 6.910 - 6.910
52wk Range 3.280 - 9.821
Shares Outstanding 41,957,197
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Which stocks are gapping on Monday? ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill

Performance

YTD
-16.7%
-16.7%
1 Month
-13.0%
-13.0%
3 Month
+78.6%
+78.6%
6 Month
+3.1%
+3.1%
1 Year
+4.9%
+4.9%

More News

Read More
News headline image
Top stock movements in today's session. ↗
Via Chartmill
News headline image
What to Expect from Verrica Pharmaceuticals's Earnings ↗
Via Benzinga
News headline image
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Top movers in Friday's pre-market session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Posts Profit in Fiscal Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 12, 2025 ↗
Via Benzinga
News headline image
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Verrica Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, Verrica Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does Verrica Pharmaceuticals Inc. - Common Stock trade on?
Verrica Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock?
The ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock is VRCA on the Nasdaq Stock Market
What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?
The current price of Verrica Pharmaceuticals Inc. - Common Stock is 6.910
When was Verrica Pharmaceuticals Inc. - Common Stock last traded?
The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 02/06/26 04:00 PM ET
What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?
The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 289.92M
How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?
Verrica Pharmaceuticals Inc. - Common Stock has 290M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.